The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. METHODS: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. RESULTS: At the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cholesterol levels. Patients were followed for a median of 31 months. At a prespecified interim analysis that included 1135 primary end-point events (71% of the projected total number), the independent data and safety monitoring board recommended termination of the trial for futility. As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, respectively; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P=0.52) and did not have a significant effect on any component of the primary end point or total mortality. The median C-reactive protein level was 0.2 mg per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons). CONCLUSIONS: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last factor probably also contributed to the rise in LDL cholesterol observed in the placebo group, in the on-treatment analysis in the alirocumab group, and in previous trials involving patients who had an acute coronary syndrome. 5,21”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, early generations of CETP inhibitors were either associated with off-target adverse effects with safety concerns, or had no significant or only modest LDL-C lowering and thus failed to demonstrate cardiovascular benefit, leading to a loss of enthusiasm in this drug class [[7], [8], [9], [10]].”
From Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Anacetrapib reduced major coronary events by 9% over a median of 4.1 years [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“More recently, the REVEAL study investigated anacetrapib in > 30 000 patients with atherosclerotic vascular disease and resulted in a lower incidence of MACE compared with placebo after 4 years, with no safety concerns [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events. 362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events.362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [85]
In the citing paper
“However, three out of four prospective studies with CETP inhibitors had to be terminated due to increased mortality in the treatment group or due to futility (Table 3).”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [107]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 1,004
Jensen, M. K., Aroner, S. A., Mukamal, K. J., Furtado, J. D., Post, W. S., Tsai, M. Y., Tjønneland, A. M., Polak, J. F., Rimm, E. B., Overvad, K., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031276 · Cited by 109
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 116
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 109
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Harada‐Shiba, M., Curcio, D. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415820 · Cited by 116
Self-citationCholesteryl ester transfer protein and its inhibitors
Shrestha, S., Wu, B. J., Guiney, L., Barter, P. J., & Rye, K. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082735 · Cited by 109
Self-citationWong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
High-density lipoproteins and immune response: A review
Grao‐Cruces, E., Lopez-Enriquez, S., Martín, M. E., & la Paz, S. M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.009 · Cited by 104
HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction
Zewinger, S., Speer, T., Kleber, M. E., Scharnagl, H., Woitas, R., Lepper, P. M., Pfahler, K., Seiler, S., Heine, G. H., März, W., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050482 · Cited by 103
Adorni, M. P., Ronda, N., Bernini, F., & Zimetti, F. (2021) · Cells · doi:10.3390/cells10030574 · Cited by 110
PET Imaging of Atherosclerotic Disease: Advancing Plaque Assessment from Anatomy to Pathophysiology
Evans, N. R., Tarkin, J. M., Chowdhury, M. M., Warburton, E. A., & Rudd, J. H. F. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0584-3 · Cited by 109
Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies
Furtado, J. D., Yamamoto, R., Melchior, J., Andraski, A. B., Gamez-Guerrero, M., Mulcahy, P., He, Z., Cai, T., Davidson, W. S., & Sacks, F. M. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311607 · Cited by 103
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 126
Kastelein, J. J. P., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh, G. K., Al‐Saady, N., Koeijvoets, M., Hunter, J. A., Johnson‐Levonas, A. O., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62115-2 · Cited by 102
Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)
Potì, F., Simoni, M., & Nofer, J. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu136 · Cited by 103
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
Self-citationAcharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., Sedlis, S. P., Kostuk, W. J., Spertus, J. A., Dada, M. R., CHAITMAN, B. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.051 · Cited by 100
Self-citationHigh-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 101
Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis
Trinder, M., Genga, K. R., Kong, H. J., Blauw, L. L., Lo, C., Li, X., Cirstea, M. S., Wang, Y., Rensen, P. C. N., Russell, J. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1157oc · Cited by 98
Lawlor, D. A., Nordestgaard, B. G., Benn, M., Zuccolo, L., Tybjærg‐Hansen, A., & Smith, G. D. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht081 · Cited by 96
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
HDL and cardiovascular disease
Nicholls, S. J., & Nelson, A. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.017 · Cited by 104
Self-citationOgura, M., Hori, M., & Harada‐Shiba, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306665 · Cited by 96
Bartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002436 · Cited by 96
Adipocytes, aldosterone and obesity-related hypertension
Cat, A. N. D., Friederich‐Persson, M., White, A. D., & Touyz, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0025 · Cited by 94
Beginning to Understand High-Density Lipoproteins
Santos‐Gallego, C. G., Badimon, J. J., & Rosenson, R. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.001 · Cited by 96
Role of Niacin in Current Clinical Practice: A Systematic Review
Garg, A., Sharma, A., Krishnamoorthy, P. M., Garg, J., Virmani, D., Sharma, T., Stefanini, G. G., Kostis, J. B., Mukherjee, D., & Sikorskaya, E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.07.038 · Cited by 95
Alcohol and Cardiovascular Disease: How Much is Too Much?
Toma, A., Paré, G., & Leong, D. P. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0647-0 · Cited by 95
Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions
Burgess, S., Freitag, D. F., Khan, H., Gorman, D. N., & Thompson, S. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108891 · Cited by 95
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 96
HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics
Vitali, C., Khetarpal, S. A., & Rader, D. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0940-0 · Cited by 96
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Kim, N. H., & Kim, S. G. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0001 · Cited by 98
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 99
Schwartz, G. G., Ballantyne, C. M., Barter, P. J., Kallend, D. G., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Nicholls, S. J., OLSSON, A. G., Shah, P. K., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3833 · Cited by 94
Self-citationNicholls, S. J., Lincoff, A. M., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Grainger, C., Menon, V., Montalescot, G., Rader, D. J., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.007 · Cited by 94
Self-citationGoldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 99
Quantification of HDL Particle Concentration by Calibrated Ion Mobility Analysis
Hutchins, P. M., Ronsein, G. E., Monette, J. S., Pamir, N., Wimberger, J., He, Y., Anantharamaiah, G. M., Kim, D. S., Ranchalis, J., Jarvik, G. P., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.228114 · Cited by 92
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Self-citationThe perils of surrogate endpoints
Weintraub, W. S., Lüscher, T. F., & Pocock, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv164 · Cited by 95
Adams, V., Besler, C., Fischer, T., Riwanto, M., Noack, F., Höllriegel, R., Oberbach, A., Jehmlich, N., Völker, U., Winzer, E. B., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301684 · Cited by 91
Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Morton, A. M., Koch, M., Mendivil, C. O., Furtado, J. D., Tjønneland, A., Overvad, K., Wang, L., Jensen, M. K., & Sacks, F. M. (2018) · JCI Insight · doi:10.1172/jci.insight.98045 · Cited by 91
Georgakis, M. K., Malik, R., Anderson, C. D., Parhofer, K. G., Hopewell, J. C., & Dichgans, M. (2019) · Brain · doi:10.1093/brain/awz413 · Cited by 91
Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0051 · Cited by 97
Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Sarraju, A., & Nissen, S. E. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00979-8 · Cited by 96
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 91
Safety and efficacy of ezetimibe: A meta-analysis
Savarese, G., De Ferrari, G. M., Rosano, G. M. C., & Perrone-Filardi, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.103 · Cited by 88
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
MicroRNA Control of High-Density Lipoprotein Metabolism and Function
Rayner, K. J., & Moore, K. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.300645 · Cited by 91
The role of the lymphatic system in cholesterol transport
Huang, L., Elvington, A., & Randolph, G. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00182 · Cited by 93
Joshi, P. H., Toth, P. P., Lirette, S. T., Griswold, M. E., Massaro, J. M., Martin, S. S., Blaha, M. J., Kulkarni, K. R., Khokhar, A. A., Correa, A., et al. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314543890 · Cited by 91
Kootte, R. S., Smits, L. P., van der Valk, F. M., Dasseux, J., Keyserling, C., Barbaras, R., Paolini, J. F., Santos, R. D., van Dijk, T. H., Dallinga‐Thie, G. M., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m055665 · Cited by 89
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
White, C. R., Garber, D. W., & Anantharamaiah, G. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r051367 · Cited by 91
Beaudoin, M., Gupta, R. M., Won, H., Lo, K. S., Do, R., Henderson, C. A., Lavoie-St-Amour, C., Langlois, S., Rivas, D., Lehoux, S., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305534 · Cited by 88
Self-citationRay, K. K., Ditmarsch, M., Kallend, D. G., Niesor, E. J., Suchánková, G., Upmanyu, R., Anzures‐Cabrera, J., Lehnert, V., Pauly-Evers, M., Holme, I., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu105 · Cited by 88
Self-citationPrinciples and Applications of Rabbit Models for Atherosclerosis Research
Fan, J., Chen, Y., Yan, H., Niimi, M., Wang, Y., & Liang, J. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17018 · Cited by 87
Zuber, V., Gill, D., Ala‐Korpela, M., Langenberg, C., Butterworth, A. S., Bottolo, L., & Burgess, S. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa216 · Cited by 91
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 94
High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity
Rohatgi, A. K. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.05.004 · Cited by 87
The Relationships Between Cardiovascular Disease and Diabetes
Kovacic, J. C., Castellano, J. M., Farkouh, M. E., & Fuster, V. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.007 · Cited by 89
Joo, H. J., Cho, S.-A., Hong, S. J., Hur, S., Bae, J., Choi, D., Ahn, Y., Park, J., Choi, R. K., Choi, D., et al. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0374-5 · Cited by 85
Nomura, A., Won, H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D. M., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab164 · Cited by 87
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
Self-citationThe Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 86
Qiu, C., Zhao, X., Zhou, Q., & Zhang, Z. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0604-5 · Cited by 89
The role of adiponectin in cholesterol efflux and HDL biogenesis and metabolism
Hafiane, A., Gasbarrino, K., & Daskalopoulou, S. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153953 · Cited by 84
Ballantyne, C. M., Ditmarsch, M., Kastelein, J. J. P., Nelson, A. J., Kling, D. F., Hsieh, A., Curcio, D. L., Maki, K. C., Davidson, M. H., & Nicholls, S. J. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.098 · Cited by 84
Self-citationHDL and cholesterol: life after the divorce?
Vickers, K. C., & Remaley, A. T. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r035964 · Cited by 87
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease
Rahman, M. S., Murphy, A. J., & Woollard, K. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.34 · Cited by 86
Ahmed, H. M., Miller, M. J., Nasir, K., McEvoy, J. W., Herrington, D. M., Blumenthal, R. S., & Blaha, M. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv305 · Cited by 83
HDL functionality in type 1 diabetes
Ganjali, S., Dallinga‐Thie, G. M., Simental‐Mendía, L. E., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.018 · Cited by 84
Singh, K., Chandra, A., Sperry, T., Joshi, P. H., Khera, A., Virani, S. S., Ballantyne, C. M., Otvos, J. D., Dullaart, R. P. F., Gruppen, E. G., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045713 · Cited by 83
Self-citationEffect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
Kaur, N., Pandey, A. K., Negi, H., Shafiq, N., Reddy, S., Kaur, H., Chadha, N., & Malhotra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094585 · Cited by 83
Liu, C., Zhang, Y., Ding, D., Li, X., Yang, Y., Li, Q., Zheng, Y., Wang, D., & Ling, W. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.111 · Cited by 85
van der Tuin, S. J. L., Zhuang, L., Berbée, J. F. P., Verkouter, I., Ringnalda, L. E., Neele, A. E., van Klinken, J. B., Rensen, S. S., Fu, J., de Winther, M. P. J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008105 · Cited by 84
Mendelian randomization studies
Ference, B. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000247 · Cited by 84
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Akioyamen, L. E., Genest, J. J., Chu, A., Inibhunu, H., Ko, D. T., & Tu, J. V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.10.012 · Cited by 86
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies
Revilla, G., Cedó, L., Tondo, M., Moral, A., Pérez, J. I., Corcoy, R., Lerma, E., Fusté, V., Reddy, S. T., Blanco‐Vaca, F., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.012 · Cited by 81
Millwood, I. Y., Bennett, D., Holmes, M. V., Boxall, R., Guo, Y., Bian, Z., Yang, L., Sansome, S., Chen, Y., Du, H., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4177 · Cited by 83
Kallend, D. G., Reijers, J. A. A., Bellibas, S. E., Bobillier, A., Kempen, H. J. M., Burggraaf, J. L. I., Moerland, M., & Wijngaard, P. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv041 · Cited by 80
Self-citationBrandts, J., & Ray, K. K. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.004 · Cited by 84
HDL, Atherosclerosis, and Emerging Therapies
Hafiane, A., & Genest, J. J. (2013) · Cholesterol · doi:10.1155/2013/891403 · Cited by 82
CETP Inhibition: Past Failures and Future Hopes
Kosmas, C. E., DeJesus, E., Rosario, D., & Vittorio, T. J. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s32667 · Cited by 80
High-Density Lipoproteins and the Immune System
Kaji, H. (2013) · Journal of Lipids · doi:10.1155/2013/684903 · Cited by 81
The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 77
Self-citationGuérin, M., Silvain, J., Gall, J., Darabi, M., Berthet, M., Frisdal, É., Hauguel‐Moreau, M., Zeitouni, M., Kernéis, M., Lattuca, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.080 · Cited by 81
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Tuteja, S., & Rader, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.79 · Cited by 77
Angeloni, E., Paneni, F., Landmesser, U., Benedetto, U., Melina, G., Lüscher, T. F., Volpe, M., Sinatra, R., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht163 · Cited by 79
Atherosclerosis and Coronary Artery Disease
Zaromitidou, M., Siasos, G., Παπαγεωργίου, Ν., Oikonomou, E. K., & Tousoulis, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00002-1 · Cited by 82
HDL-cholesterol and cardiovascular disease: rethinking our approach
Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77
HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients
Annema, W., Dikkers, A., de Boer, J. F., Dullaart, R. P. F., Sanders, J., Bakker, S. J. L., & Tietge, U. J. F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090857 · Cited by 79
McGarrah, R. W., Craig, D. M., Haynes, C. S., Dowdy, Z. E., Shah, S. H., & Kraus, W. E. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.012 · Cited by 77
Pharmacological Intervention to Modulate HDL: What Do We Target?
Woudberg, N. J., Pedretti, S., Lecour, S., Schulz, R., Vuilleumier, N., James, R. W., & Frias, M. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00989 · Cited by 80
Beyond Coronary Calcification, Family History, and C-Reactive Protein
Mody, P. S., Joshi, P. H., Khera, A., Ayers, C. R., & Rohatgi, A. K. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.538 · Cited by 76
Cholesterol efflux capacity: An introduction for clinicians
Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 78
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 80
Salahuddin, T., Natarajan, B., Playford, M. P., Joshi, A. A., Teague, H., Masmoudi, Y., Selwaness, M., Chen, M. Y., Bluemke, D. A., & Mehta, N. N. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv339 · Cited by 77
HDL-cholesterol in coronary artery disease risk: Function or structure?
Pérez-Méndez, O. A., González‐Pacheco, H., Martínez‐Sánchez, C., & Franco, M. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.12.001 · Cited by 80
Kühnast, S., van der Tuin, S. J. L., van der Hoorn, J. W. A., van Klinken, J. B., Simic, B., Pieterman, E. J., Havekes, L. M., Landmesser, U., Lüscher, T. F., van Dijk, K. W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu319 · Cited by 79
Metadata
- Authors
- Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Mundl, H., Nicholls, S. J., Shah, P. K., Tardif, J.-C., & Wright, R. S.
- Affiliations
- Denver VA Medical Center (US)
- Linköping University (SE)
- F. Hoffmann-La Roche AG (CH)
- Baylor College of Medicine (US)
- University of Zurich (CH)
- Oslo University Hospital (NO)
- St. Michael's Hospital (CA)
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-11-29
- Volume
- 367
- Issue
- 22
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118825330
- Cited by
- 2,022
- References
- 35
- Citations by year
- 2026: 66 · 2025: 82 · 2024: 81 · 2023: 89 · 2022: 103 · 2021: 128 · 2020: 109 · 2019: 141 · 2018: 164 · 2017: 195 · 2016: 222 · 2015: 244 · 2014: 191 · 2013: 190 · 2012: 7
- FWCI
- 206.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche
- CSL Behring
- Amarin Corporation
- Anthera
- Kowa Company
- Servier
- Esperion Therapeutics
- Genentech
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- dalcetrapib, cholesteryl ester transfer protein inhibition, HDL cholesterol, acute coronary syndrome, cardiovascular risk, futility, LDL cholesterol, C-reactive protein, systolic blood pressure, myocardial infarction, ischemic stroke, unstable angina, cardiovascular mortality, lipid-lowering therapy
- MeSH terms
- Aged, Amides, Anticholesteremic Agents, Apolipoproteins, Blood Pressure, C-Reactive Protein, Cardiovascular Diseases, Esters, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Sulfhydryl Compounds, Triglycerides, Biomarkers, Cholesterol Ester Transfer Proteins, Acute Coronary Syndrome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
